Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: An 8.5-year analysis of susceptibilities of candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing

Journal of Clinical Microbiology

Volumn 45, Issue 6, 2007, Pages 1735-1745

  Pfaller, M A ^a   Diekema, D J ^a   Gibbs, D L ^b   Newell, V A ^b   Meis, Jacques F ^c   Gould, Ian M ^d   Fu, Wang ^e   Colombo, Arnaldo Lopez ^f   Rodriguez Noriega, E ^g   Finquelievich, Jorge ^h   Tiraboschi, Nora ⁱ   Ellis, David ^j   Fameree, Dominique ^k   Van Den Abeele, Anne Marie ^l   Senterre, Jean Marc ^m   Rennie, Robert ⁿ   Sanche, Stephen ^o   Bijie, Hu ^p   Xu, Yingchun ^q   Zhong, Nan Shan ^r   Rivas, Pilar ^s   De Bedout, Catalina ^t   Mendez, Matilde ^u   Vega, Ricardo ^u   Mallatova, Nada ^v   Dobiasova, Stanislava ^l   Ayabaca, Julio ^w   Zurita, Jeannete ^x   Mallie, M ^y   Candolfi, E ^z   Fegeler, W ^aa   Haase, G ^ab   Rodloff, A C ^ac   Bar, W ^ad   Czaika, V ^ae   Petrikos, George ^af   Erzsébet, Puskás ^ag   Nagy, Elisabeth ^ah   Gyula, Mestyan ^ai   Nikolova, Radka ^aj   Banerjee, Uma ^ak   Keller, Nathan ^al   Tullio, Vivian ^am   Schito, Gian Carlo ^an   D'Antonio, Domenico ^ao   Martino, Pietro ^l   Peng, N G Kee ^ap   Alpuche, Celia ^aq   Santos, Jose ^aq   Ortero, Rayo Morfin ^g   Zaidi, Mussaret ^ar   Lingaas, Egil ^as   Dzierzanowska, Danuta ^at   Pawliszyn, Waclaw ^au   Martins, Mariada Luz ^av   Albuquerque, Luis ^aw   Rosado, Laura ^ax   Velho, Rosa ^aw   Amorim, Jose ^ay   Ilina, Vera N ^az   Kretchikova, Olga I ^ba   Klyasova, Galina A ^bb   Rozanova, Sophia M ^bc   Multykh, Irina G ^bd   Klimko, Nikolay N ^be   Agapova, Elena D ^bf   Dmitrieva, Natalya V ^bg   Al Rasheed, Abdul Mohsen ^bh   Shibl, Atef ^bi   Trupl, Jan ^bj   Helena, Hupkova ^bk   Hoosen, Anwar ^bl   Wadula, Jeannette ^bm   Van Rensburg, M N Janse ^bn   Duse, Adriano ^bo   Lee, Kyungwon ^bp   Kim, Mi Na ^bq   Del Palacio, A ^br   Sanchez Sousa, Aurora ^bs   Bille, Jacques ^bt   Muhlethaler, K ^bu   Chang, Shan Chwen ^bv   Wang, Jen Hsien ^bw   Gur, Deniz ^bx   Korten, Volkan ^by   Paul, John ^bz   Brown, Derek ^ca   Kibbler, Chris ^cb   Weightman, Nigel ^cc   Rennison, Claire ^cd   Barton, Richard ^ce   Barnes, Rosemary ^cf   Vazquez, Jose ^cg   Larone, Davise ^ch   Rinaldi, Mike ^ci   Reyes, Heidi ^cj   Santiago, Axel ^ck   more..

^a UNIVERSITY OF IOWA   (United States)

^b Giles Scientific Inc   (United States)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d NHS GRAMPIAN   (United Kingdom)

^e FUDAN UNIVERSITY   (China)

^f FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^g UNIVERSITY OF GUADALAJARA   (Mexico)

^h UNIVERSIDAD DE BUENOS AIRES   (Argentina)

ⁱ Hospital Escuela Gral   (Argentina)

^j WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^k CHU de Jumet   (Belgium)

^l CHU de Jumet ^*  (Italy)

^m Centre Hospitalier Regional de La Citadelle   (Belgium)

ⁿ UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^o ROYAL UNIVERSITY HOSPITAL   (Canada)

^p ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

^q PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^r GUANGZHOU MEDICAL UNIVERSITY   (China)

^s Instituto Nacional de Cancerología   (Colombia)

^t CIB   (Colombia)

^u HOSPITAL MILITAR CENTRAL   (Colombia)

^v Hospital Ceske Budejovice   (Czech Republic)

^w Hospital FF AA HG1   (Ecuador)

^x HOSPITAL VOZANDES   (Ecuador)

^y UNIV MONTPELLIER   (France)

^z Inst Parasitol et de Pathol Trop   (France)

^aa UNIVERSITY OF MÜNSTER   (Germany)

^ab RWTH AACHEN UNIVERSITY   (Germany)

^ac Inst F Med Informatik Stat E   (Germany)

^ad CARL THIEM KLINIKUM   (Germany)

^ae Humaine Kliniken   (Germany)

^af LAIKO GENERAL HOSPITAL   (Greece)

^ag Hospital of BAZ County   (Hungary)

^ah UNIVERSITY OF SZEGED   (Hungary)

^ai UNIVERSITY OF PÉCS   (Hungary)

^aj Szent Laszlo Hospital   (Hungary)

^ak ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^al SHEBA MEDICAL CENTER   (Israel)

^am UNIVERSITY OF TURIN   (Italy)

^an UNIVERSITY OF GENOA   (Italy)

^ao Ospedale Civile di Pescara   (Italy)

^ap UNIVERSITY OF MALAYA   (Malaysia)

^aq HOSPITAL GENERAL DE MÉXICO   (Mexico)

^ar Hospital General O'Horan   (Mexico)

^as OSLO UNIVERSITY HOSPITAL   (Norway)

^at CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^au Szpital Uniwersyteckiego   (Poland)

^av INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^aw CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^ax NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^ay HOSPITAL DE SANTO ANTÓNIO   (Portugal)

^az Novosibirsk State Regional Clinical Hospital   (Russian Federation)

^ba Scientific Research Institute of Antimicrobial Chemotherapy   (Russian Federation)

^bb NATIONAL RESEARCH CENTER FOR HEMATOLOGY   (Russian Federation)

^bc City Hospital No 40   (Russian Federation)

^bd Territory Center of Laboratory Diagnostics   (Russian Federation)

^be Research Institute of Mycology   (Russian Federation)

^bf Irkutsk Regional Children's Hospital   (Russian Federation)

^bg Oncological Research Center   (Russian Federation)

^bh The General Directorate of Armed Forces Health Services   (Saudi Arabia)

^bi KING SAUD UNIVERSITY   (Saudi Arabia)

^bj National Cancer Center   (United States)

^bk St Cyril and Method Hospital   (Slovakia)

^bl SEFAKO MAKGATHO HEALTH SCIENCES UNIVERSITY   (South Africa)

^bm UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^bn UNIVERSITY OF THE FREE STATE   (South Africa)

^bo UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^bp Yonsei University College of Medicine   (South Korea)

^bq Asan Medical Center   (South Korea)

^br HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^bs HOSPITAL RAMÓN Y CAJAL   (Spain)

^bt LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^bu UNIVERSITY OF BERN   (Switzerland)

^bv NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^bw CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^bx HACETTEPE UNIVERSITY   (Turkey)

^by MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^bz ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^ca ADDENBROOKE S HOSPITAL   (United Kingdom)

^cb ROYAL FREE HOSPITAL   (United Kingdom)

^cc FRIARAGE HOSPITAL   (United Kingdom)

^cd ROYAL VICTORIA INFIRMARY   (United Kingdom)

^ce LEEDS GENERAL INFIRMARY   (United Kingdom)

^cf CARDIFF UNIVERSITY   (United Kingdom)

^cg HENRY FORD HOSPITAL   (United States)

^ch WEILL CORNELL MEDICAL CENTER   (United States)

^ci UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^cj Gen del Este Domingo Luciani   (Venezuela)

^ck Universitario de Caracas   (Venezuela)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

AFRICA; AGAR GEL DIFFUSION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ASIA; BIOTYPE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA RUGOSA; CANDIDA TROPICALIS; CRYPTOCOCCUS; EUROPE; FUNGUS ISOLATION; GEOGRAPHICAL VARIATION (SPECIES); HANSENULA; HOSPITAL DEPARTMENT; IMAGE ANALYSIS; MIDDLE EAST; NONHUMAN; NORTH AMERICA; PICHIA; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RHODOTORULA; SACCHAROMYCES; SOUTH AND CENTRAL AMERICA; SPECIES IDENTIFICATION; TRICHOSPORON;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA RUGOSA; CANDIDA TROPICALIS;

EID: 34250621370     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00409-07     Document Type: Review

References (45)

1. Alexander, B. D., and M. A. Pfaller. 2006. Contemporary tools for the diagnosis and management of invasive mycoses. Clin. Infect. Dis. 43:S15-S27.
2. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgen, J. C. Schonheyden, and M. Trede. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and number of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43:4434-4440.
3. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. H. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, and D. W. Warnock for the Cryptococcal Disease Active Surveillance Group. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
4. Chen, A., and J. D. Sobel. 2005. Emerging azole antifungals. Expert Opin. Emerg. Drugs 10:21-33.
5. Diekema, D. J., B. Petroelje, S. A. Messer, R. J. Hollis, and M. A. Pfaller. 2005. Activities of available and investigational antifungal agents against Rhodotorula species. J. Clin. Microbiol. 43:476-478.
6. Fridkin, S. K. 2005. The changing face of fungal infections in health care settings. Clin. Infect. Dis. 41:1455-1460.
7. Hajjeh, R. A., A. N. Sofair, I. H. Harrison, G. M. Lyon, B. A. Arthington-Skaggs, S. A. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519-1527.
8. Hazen, K. C. 1995. New and emerging yeast pathogens. Clin. Microbiol. Rev. 8:462-478.
9. Hazen, K. C., E. J. Baron, A. L. Colombo, C. Girmenia, A. Sanchez-Sousa, A. del Palacio, C. de Bedout, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2003. Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J. Clin. Microbiol. 41:5623-5632.
10. Kidd, S. E., F. Hagan, R. L. Tscharke, et al. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. USA 101:17258-17263.
11. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535.
12. Matsue, K., H. Uryu, M. Koseki, N. Asada, and M. Takeachi. 2006. Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin. Infect. Dis. 42:753-757.
13. Meis, J., M. Petrou, J. Bille, D. Ellis, D. Gibbs, and the Global Antifungal Surveillance Group. 2000. A global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn. Microbiol. Infect. Dis. 36:215-223.
14. Morera-Lopez, Y., J. M. Torres-Rodriguez, T. Jimenez-Cabello, and T. Baro-Tomas. 2005. Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole. Med. Mycol. 43:505-510.
15. Morgan, J., K. M. McCarthy, S. Gould, K. Fan, B. Arthington-Skaggs, N. Igbal, K. Stamey, R. A. Hajjeh, and M. E. Brandt for the Gauting Cryptococcal Surveillance Initiative Group. 2006. Cryptococcus gattii infection: characteristics and epidemiology of cases identified in a South African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43:1077-1080.
16. National Committee for Clinical Laboratory Standards. 2004. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard M44-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
17. Nucci, M., and K. A. Marr. 2005. Emerging fungal diseases. Clin. Infect. Dis. 41:521-526.
18. Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743.
19. Pappas, P. G., J. H. Rex, J. Lee, R. J. Hamill, R. A. Larsen, W. Powderly, C. A. Kauffman, N. Hyslop, J. E. Mangino, S. Chapman, H. W. Horowitz, J. E. Edwards, and W. E. Dismukes. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
20. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards for the Infectious Diseases Society of America. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
21. Perfect, J. R., K. A. Marr, T. J. Walsh, et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
22. Pfaller, M. A. 2005. Antifungal susceptibility testing methods. Curr. Drug Targets 6:929-943.
23. Pfaller, M. A., and D. J. Diekema. 2002. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 40:3551-3557.
24. Pfaller, M. A., and D. J. Diekema. 2004. Rare and emerging opportunistic fungal pathogens: concerns for resistance beyond Candida albicans and Aspergillus fumigatus. J. Clin. Microbiol. 42:4419-4431.
25. Pfaller, M. A., K. C. Hazen, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 42:3607-3692.
26. Pfaller, M. A., D. J. Diekema, M. G. Rinaldi, R. Barnes, B. Hu, A. V. Veselov, N. Tiraboschi, E. Nagy, D. L. Gibbs, and the Global Antifungal Surveillance Group. 2005. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-ycar analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 43:5848-5859.
27. Pfaller, M. A., L. Boyken, S. A. Messer, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2005. Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 43: 5208-5213.
28. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
29. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive break-points for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
30. Pfaller, M. A., P. G. Pappas, and J. R. Wingard. 2006. Invasive fungal pathogens: current epidemiological trends. Clin. Infect. Dis. 43:S3-S14.
31. Pfaller, M. A., D. J. Diekema, M. Mendez, C. Kibbler, P. Erzsebet, S. C. Chang, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group. 2006. Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol. 44:3551-3556.
32. Pfaller, M. A., D. J. Diekema, A. L. Colombo, C. Kibbler, K. P. Ng, D. L. Gibbs, V. A. Newell, and the Global Antifungal Surveillance Group. 2006. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program. J. Clin. Microbiol. 44:3578-3582.
33. Pfaller, M. A., and R. N. Jones for the Microbiology Resource Committee of the College of American Pathologists. 2006. Performance accuracy of antibacterial and antifungal susceptibility test methods: report from the College of American Pathologists (CAP) Microbiology Surveys Program (2001-2003). Arch. Pathol. Lab. Med. 130:767-778.
34. Pfaller, M. A., and D. J. Diekema. 2007. The epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
35. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2007. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J. Clin. Microbiol. 45:70-75.
36. Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. 2007. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45:796-802.
37. Rees, J. R., R. W. Pinner, R. A. Hajjeh, M. E. Brandt, and A. L. Reingold. 1998. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of a population-based laboratory active surveillance. Clin. Infect. Dis. 27:1138-1147.
38. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
39. Sorrell, T. C. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155-168.
40. Spanakis, E. K., G. Aperis, and E. Mylonakis. 2006. New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. Clin. Infect. Dis. 43:1060-1068.
41. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
42. Tay, S. T., T. T. Haryanti, K. P. Ng, M. Y. Rohani, and H. Hamimah. 2006. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neofor mans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 49:324-330.
43. Trilles, L., B. Fernandez-Torres, M. dos Santos Lazera, B. Wanke, and J. Guarro. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42:4815-4817.
44. Walsh, T. J., A. Groll, J. Hiemenz, R. Flemming, E. Roilides, and E. Anaissie. 2004. Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(Suppl. 1):48-66.
45. Zaoutis, T. E., J. Argon, J. Chu, J. A. Berlin, T. J. Walsh, and C. Feudtner. 2005. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin. Infect. Dis. 41:1232-1239.